MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MTVA MetaVia Inc

Closed Good Friday 04-17 16:00:00 EDT

0.7390

+0.0047

+0.64%

盘后0.7400

+0.0010+0.14%

19:59 EDT

High0.7479	Low0.6470	Vol598.93K
Open0.7000	D1 Closing0.7343	Amplitude13.74%
Mkt Cap6.40M	Tradable Cap1.73M	Total Shares8.65M
T/O420.88K	T/O Rate25.63%	Tradable Shares2.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.739,"timestamp":1744920000000,"preClose":0.7343,"halted":0,"volume":598934,"hourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.739,"latestTime":"19:59 EDT","volume":74920,"amount":56411.927041,"timestamp":1744934392880},"delay":0,"floatShares":2336574,"shares":8654869,"eps":-3.56,"marketStatus":"Closed Good Friday","change":0.0047,"latestTime":"04-17 16:00:00 EDT","open":0.7,"high":0.7479,"low":0.647,"amount":420875.6833253,"amplitude":0.13741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.56,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.7343,"preHourTrading":{"tag":"盘前","latestPrice":0.7155,"preClose":0.7323,"latestTime":"09:29 EDT","volume":15573,"amount":11280.1343616,"timestamp":1744896580399},"postHourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.739,"latestTime":"19:59 EDT","volume":74920,"amount":56411.927041,"timestamp":1744934392880},"volumeRatio":0.11595326897331375},"requestUrl":"/m/hq/s/MTVA","defaultTab":"news","newsList":[{"id":"2527021363","title":"MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2527021363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527021363?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 19:58","pubTimestamp":1744804680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 07:58 ET (11:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2527253442","title":"MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…","url":"https://stock-news.laohu8.com/highlight/detail?id=2527253442","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527253442?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 18:27","pubTimestamp":1744799220,"startTime":"0","endTime":"0","summary":"On April 15, 2025, MetaVia Inc.  announced positive results from the Phase 1 Part 2 multiple ascending dose  trial of DA-1726 in obesity. The results showed that the cohort receiving 32 mg of DA-1726 with no titration had a maximum reduction in body weight from baseline ranging up to -6.3% and a mean body weight reduction of -4.3% . In addition, patients in the 32 mg cohort had a mean waist circumference reduction of 1.6 inches along with a mean reduction in fasting glucose of -5.3 mg/dL. Importantly, gastrointestinal  adverse events  were generally mild and most were only seen after the first dose and resolved within 24 hours of occurrence.The following chart shows the average weight loss on Day 26 for the different dosing cohorts. The 4 mg cohort had an outlier that skewed the overall average weight loss, however the 8 mg, 16 mg, and 32 mg cohorts show a clear dose response.Due to the strong tolerability profile of DA-1726, the company w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-positive-phase-1-mad-102700443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527425040","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425040?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 01:53","pubTimestamp":1744739611,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, CotyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DOW","AUR","COTY","NKE","CMPS","CVX","FLNC","LU1223082519.USD","NEM","ADM","LU0795875086.SGD","AMAT","PEP","FMC","LU2468319806.SGD","XOM","LU1280957306.USD","LU0788108826.HKD","SPNT","PNC","VLO","RDFN","CTVA","CHD","SKYE","CAT","IE00B5949003.HKD","ACI","HXL","IE00BBT3K403.USD","HWM","LU2249611893.SGD","BK4109","HUN","SEDG","JNJ","MP","EOSE","HPE","ALB","LVS","MTVA","HRL","CYTK","BK4108"],"gpt_icon":1},{"id":"2527412684","title":"Metavia Shares up 6.5% After Its Experimental Obesity Drug Shows Promise in Early-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412684?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 21:31","pubTimestamp":1744723915,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527971134","title":"BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527971134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527971134?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:47","pubTimestamp":1744717676,"startTime":"0","endTime":"0","summary":"BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study** Shares of drug developer MetaVia MTVA.O rise 17.9% to $2.17 premarket** Co says its experimental obesity drug showed a maximum reduction of 6.3% in body weight in a 28-day, 36-patient portion of an early-stage trial** The drug, DA-1726, on average reduced body weight by 4.3% ** Additionally, MTVA says DA-1726 showed waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33     ** \"We anticipate that greater weight loss may be seen in longer duration studies\" - co** In November, co changed its name to MetaVia from NeuroBo Pharmaceuticals** Up to last close, stock had fallen 9.4% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2527910184","title":"MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2527910184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527910184?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:05","pubTimestamp":1744715142,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual ox...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-announces-positive-results-from-part-2-of-phase-1-trial-of-da-1726?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-announces-positive-results-from-part-2-of-phase-1-trial-of-da-1726?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527999814","title":"Metavia Inc: Additional Cohorts Being Added to Determine Maximum Tolerated Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2527999814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527999814?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527749998","title":"Metavia: With No Titration, Demonstrated Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 Mg Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2527749998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527749998?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499677","title":"Metavia Announces Positive Top-Line Data From the 4-Week Phase 1 Mad Trial of Da-1726, a Novel 3:1 Ratio Glp-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-in-Class Glucose Control (Glp-1R), Waist Reduction (Gcgr), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499677?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499607","title":"Metavia Inc: Study Shows Strong Signal of Glucagon Efficacy at Day 33 at 32 Mg Dos","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499607?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527499153","title":"Metavia: Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of Da-1726 on Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499153?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:01","pubTimestamp":1744714867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0KZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2527492780","title":"MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492780","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492780?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:01","pubTimestamp":1744714860,"startTime":"0","endTime":"0","summary":"With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% andMean Weight Loss of 4.3% at Day 26 at 32 mg Dose . Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dLand Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose. Maximum Waist Circumference Reduction of3.9 Inches and Mean Reduction of 1.6 InchesDemonstrates Strong Signal ofGlucagon Efficacy at Day 33 at 32 mg Dose. Additional Cohorts Being Added to Determine Maximum Tolerated Dose. Planned Phase 1 Part 3 to Include Wegovy Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose  Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin  an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-110100485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4202","BK4139","OXM","BK4023","LU1169589451.USD","LU1169590202.USD","BMI","MTVA","PK","BK4144","PD","BK4181","BK4157","BK4590","BK4218"],"gpt_icon":0},{"id":"2521073767","title":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521073767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521073767?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 15:55","pubTimestamp":1742802941,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty EnergyMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed compani","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q70IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRM","IE00B0JY6N72.USD","ALNY","LU2264538146.SGD","BK4607","LU0642271901.SGD","LU2362540622.SGD","IE00BFTCPJ56.SGD","BRZE","LBRT","LU0738911758.USD","IE00B5949003.HKD","IE00B19Z3B42.SGD","LU0256863811.USD","LU2456880835.USD","RXST","SLB","FDX","LU1720051017.SGD","LU0251142724.SGD","HUBS","LEN","BBIO","LU0238689110.USD","LU0417517546.SGD","LU1201861249.SGD","NOV","IONS","IE00B4R5TH58.HKD","MTVA","LU2361045086.USD","DRI","LU0719512351.SGD","LU2458330243.SGD","LU1951200564.SGD","LU1804176565.USD","LU1366333091.USD","LU0557290698.USD","LU2236285917.USD","LU2756315318.SGD","VRTX","LU1064131342.USD","LU1429558221.USD","ALHC","LU0056508442.USD","LU1267930227.SGD","BECN","LU0792757196.USD","LU2362541513.USD"],"gpt_icon":1},{"id":"2521929661","title":"MetaVia Inc. Reports Progress in Cardiometabolic Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2521929661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521929661?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 11:53","pubTimestamp":1742615610,"startTime":"0","endTime":"0","summary":"Neurobo Pharmaceuticals, Inc. ( ($MTVA) ) has released its Q4 earnings. Here is a breakdown of the information Neurobo Pharmaceuticals, Inc. presen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/metavia-inc-reports-progress-in-cardiometabolic-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/metavia-inc-reports-progress-in-cardiometabolic-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065732104.USD","PRGS","BK4097","MTVA"],"gpt_icon":0},{"id":"2521815252","title":"MetaVia Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521815252","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521815252?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:12","pubTimestamp":1742562720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 09:12 ET (13:12 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2520945338","title":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2520945338","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520945338?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:50","pubTimestamp":1742471448,"startTime":"0","endTime":"0","summary":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44414209/metavia-2024-eps-3-56-down-from-2-46-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"MetaVia 2024 EPS $(3.56) Down From $(2.46) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2520458331","title":"Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458331?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:31","pubTimestamp":1742470260,"startTime":"0","endTime":"0","summary":"Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025. Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect. $16.0 Million in Cash at End of Fourth Quarter Expected to Fund the Company Into the Third Quarter of 2025. CAMBRIDGE, Mass., March 20, 2025 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.Mr. Kim continued, \"In December, we reported positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . DA-1241 met the primary endpoint, achieving a reduction in alanine transaminase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GGT","MTVA","LU1878469433.USD","OXM","ALT","BK4599","BK4202"],"gpt_icon":0},{"id":"2502286335","title":"MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2502286335","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502286335?lang=en_us&edition=full_marsco","pubTime":"2025-01-10 21:05","pubTimestamp":1736514300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ --MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th Annual MASH-TAG 2025 Conference, to discuss the previously announced positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-hold-advisory-committee-meeting-130500948.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-hold-advisory-committee-meeting-130500948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","MTVA","OXM","BK4139"],"gpt_icon":0},{"id":"2495654684","title":"HC Wainwright Initiates MetaVia at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2495654684","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495654684?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 20:21","pubTimestamp":1735561274,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates MetaVia at Buy With $12 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurobopharma.com","stockEarnings":[{"period":"1week","weight":-0.4606},{"period":"1month","weight":-0.5293},{"period":"3month","weight":-0.6201},{"period":"6month","weight":-0.7561},{"period":"1year","weight":-0.7864},{"period":"ytd","weight":-0.636}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.078486},{"month":2,"riseRate":0.333333,"avgChangeRate":0.050158},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.011768},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.145474},{"month":5,"riseRate":0.25,"avgChangeRate":-0.104755},{"month":6,"riseRate":0.625,"avgChangeRate":0.103229},{"month":7,"riseRate":0.25,"avgChangeRate":-0.022415},{"month":8,"riseRate":0.125,"avgChangeRate":-0.219737},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019058},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.212992},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.100828},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.17607}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}